TABLE 1.
Parasite | Parasite stages | Type(s) of assaya | Measure(s) | Reference(s) |
---|---|---|---|---|
Plasmodium | Liver stages (sporozoites, schizonts, hypnozoites) | High-content imaging | P. berghei/P. yoelii liver schizont development | 161 |
Bioluminescence imaging | P. berghei/P. yoelii liver schizont development | 27, 162 | ||
Immunofluorescence | Development of P. chabaudi liver small (hypnozoites) and large (schizonts) forms | 33 | ||
Immunofluorescence | P. falciparum/P. vivax sporozoite invasion and development | 28, 29 | ||
Asexual blood stages (rings, trophozoites, schizonts) | Microscopic | P. falciparum/P. vivax schizont maturation | 163 | |
P. falciparum ring-stage survival | 164 | |||
Isotopic | P. falciparum intraerythrocytic growth | 4 | ||
P. falciparum intraerythrocytic growth | 5 | |||
Colorimetric | P. falciparum intraerythrocytic growth | 7 | ||
ELISA | P. falciparum intraerythrocytic growth | 6 | ||
Fluorescent DNA dye based | P. falciparum intraerythrocytic growth | 9, 165, 166 | ||
Transmission stages (gametocytes, gametes, zygotes, ookinetes, oocysts, sporozoites) | ATP bioluminescence | P. falciparum gametocyte viability | 167 | |
Flow cytometry | P. falciparum gametocyte viability | 168 | ||
Microscopic-immunofluorescence | P. falciparum male (exflagellation) and female (fluorescence, shape, size) gamete formation | 23 | ||
Microscopic | P. falciparum presence/no. of oocysts | 169 | ||
Leishmania | Amastigotes, promastigotes | Macrophage infection model | Increase in no. of amastigotes | 40, 41 |
Colorimetric | Promastigote viability | 39 | ||
Flow cytometry | No. of parasites | 42 | ||
Trypanosoma cruzi | Epimastigotes, trypomastigotes, amastigotes | Murine models of Chagas disease | Parasite burden measured using PCR, immunofluorescence, bioluminescence | 43, 44, 46, 47, 56 |
Trypanosoma brucei | Trypomastigotes, epimastigotes | PCR-RFLP with SfaNI | Detection of mutated parasite transporter and drug-resistant parasites | 69 |
Giardia lamblia | Trophozoites, cysts | Parasite culture | No. of parasites | 78 |
Colorimetric | Color change due to parasite growth | 76 | ||
Imaging | Parasite viability | 78 | ||
Bioluminescence | Luminescence signal | 80 | ||
Entamoeba histolytica | Trophozoites, cysts | Bioluminescence | ATP-dependent luciferase bioluminescence signal | 86 |
Cryptosporidium | Oocysts, gametocytes | Microscopy, qRT-PCR | Parasite invasion and growth | 100, 102–105 |
Schistosoma | Eggs, miracidiae, cercariae, schistosomulae, adult worms | Real-time parasite mobility | Worm viability and motility | 100, 101 |
Isothermal microcalorimetry | Motility | 102 | ||
Image-based high-content screening | Enzymatic and metabolic activity | 103 | ||
Fluorescence | Viability and cytotoxicity | 104, 105 | ||
Luminescence | Viability | 106 | ||
Filaria | Microfilariae, L3 larvae, adult worms | Microscopy | Motility | 132–135 |
Colorimetry | Viability | 154, 155 | ||
Worm fecundity | Microfilaria release | 134, 138 | ||
Embryogenesis | No. of embryos and stage | 134, 153, 157 | ||
Trypan blue exclusion | Viability | 151, 152 | ||
Third larval stage (L3) to fourth (L4) | Molting | 137, 141 | ||
Histology and electron microscopy | Anatomical changes | 142, 143 | ||
WormAssay (software) | Motility scoring | 156 |
qRT-PCR, quantitative reverse transcription-PCR; ELISA, enzyme-linked immunosorbent assay; PCR-RFLP, PCR-restriction fragment length polymorphism.